Latest Articles

Publication Date
Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain.

Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss …

Published: Nov. 7, 2025, midnight
Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate... - Medical Dialogues

Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate... Medical Dialogues

Published: July 2, 2025, 11:31 a.m.
Assessing Practice Patterns Regarding Use of Norethindrone Acetate in Adolescents.

Norethindrone acetate (NETA) is commonly used in adolescent patients for management of heavy menstrual bleeding, menstrual suppression, and endometriosis. Clinical guidelines do not address specific dosing strategies, clinical indications, contraindications, …

Published: Dec. 10, 2024, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!